Results 101 to 110 of about 251,092 (150)

Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease. [PDF]

J Hematol Oncol
Desantis V, Andriano A, Düking T, Hartwig O, Ingravallo G, Biondo M, Botta C, Ria R, Vacca A, Solimando AG.   +9 more
europepmc   +1 more source

Dendritic cells in multiple myeloma: from immune evasion to therapeutic potential. [PDF]

Front Immunol
Jordan MA, Morschl J, Autenrieth SE.
europepmc   +1 more source

IL-38 as a Novel Biomarker in Multiple Myeloma Patients: A Prospective Clinical Evaluation. [PDF]

Cancer Manag Res
Shen H, Zhao P, Cao J.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Multiple myeloma

Nature Reviews Disease Primers, 2017
Multiple myeloma is a malignancy of terminally differentiated plasma cells, and patients typically present with bone marrow infiltration of clonal plasma cells and monoclonal protein in the serum and/or urine. The diagnosis of multiple myeloma is made when clear end-organ damage attributable to the plasma cell proliferative disorder or when findings ...
Kumar S. K., Rajkumar V., Kyle R. A., Van Duin M., Sonneveld P., Mateos M. -V., Gay F., Anderson K. C.   +7 more
openaire   +5 more sources

Multiple Myeloma

Journal of the American Academy of Physician Assistants, 2015
This article presents a review of multiple myeloma, precursor states, and related plasma cell disorders. The clinical roles of fluorodeoxyglucose PET/computed tomography (CT) and the potential to improve the management of patients with multiple myeloma are discussed.
Tonon G., Anderson K. C.
  +9 more sources